Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 834

1.

Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP).

Cheung CC, Barnes P, Bigras G, Boerner S, Butany J, Calabrese F, Couture C, Deschenes J, El-Zimaity H, Fischer G, Fiset PO, Garratt J, Geldenhuys L, Gilks CB, Ilie M, Ionescu D, Lim HJ, Manning L, Mansoor A, Riddell R, Ross C, Roy-Chowdhuri S, Spatz A, Swanson PE, Tron VA, Tsao MS, Wang H, Xu Z, Torlakovic EE; Canadian Association of Pathologists-Association Canadienne Des Pathologistes’ National Standards Committee for High Complexity Testing (CAP-ACP NSCHCT).

Appl Immunohistochem Mol Morphol. 2019 Oct 3. doi: 10.1097/PAI.0000000000000800. [Epub ahead of print]

PMID:
31584451
2.

Crizotinib inhibition of ROS1-positive tumours in advanced non-small-cell lung cancer: a Canadian perspective.

Bebb DG, Agulnik J, Albadine R, Banerji S, Bigras G, Butts C, Couture C, Cutz JC, Desmeules P, Ionescu DN, Leighl NB, Melosky B, Morzycki W, Rashid-Kolvear F, Lab C, Sekhon HS, Smith AC, Stockley TL, Torlakovic E, Xu Z, Tsao MS.

Curr Oncol. 2019 Aug;26(4):e551-e557. doi: 10.3747/co.26.5137. Epub 2019 Aug 1.

3.

EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach.

Nicholson AG, Sauter JL, Nowak AK, Kindler HL, Gill RR, Remy-Jardin M, Armato SG 3rd, Fernandez-Cuesta L, Bueno R, Alcala N, Foll M, Pass H, Attanoos R, Baas P, Beasley MB, Brcic L, Butnor KJ, Chirieac LR, Churg A, Courtiol P, Dacic S, De Perrot M, Frauenfelder T, Gibbs A, Hirsch FR, Hiroshima K, Husain A, Klebe S, Lantuejoul S, Moreira A, Opitz I, Perol M, Roden A, Roggli V, Scherpereel A, Tirode F, Tazelaar H, Travis WD, Tsao MS, van Schil P, Vignaud JM, Weynand B, Cree I, Rusch VW, Girard N, Galateau-Salle F.

J Thorac Oncol. 2019 Sep 20. pii: S1556-0864(19)33232-0. doi: 10.1016/j.jtho.2019.08.2506. [Epub ahead of print]

PMID:
31546041
4.

A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer.

Goodwin R, Jonker D, Chen E, Kennecke H, Cabanero M, Tsao MS, Vickers M, Bohemier C, Lim H, Ritter H, Tu D, Seymour L.

Invest New Drugs. 2019 Sep 10. doi: 10.1007/s10637-019-00814-3. [Epub ahead of print]

PMID:
31506897
5.

Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel.

Marchevsky AM, Khoor A, Walts AE, Nicholson AG, Zhang YZ, Roggli V, Carney J, Roden AC, Tazelaar HD, Larsen BT, LeStang N, Chirieac LR, Klebe S, Tsao MS, De Perrot M, Pierre A, Hwang DM, Hung YP, Mino-Kenudson M, Travis W, Sauter J, Beasley MB, Galateau-Sallé F.

Mod Pathol. 2019 Sep 4. doi: 10.1038/s41379-019-0352-3. [Epub ahead of print]

PMID:
31485011
6.

Rho guanine nucleotide exchange factor ARHGEF10 is a putative tumor suppressor in pancreatic ductal adenocarcinoma.

Joseph J, Radulovich N, Wang T, Raghavan V, Zhu CQ, Tsao MS.

Oncogene. 2019 Sep 2. doi: 10.1038/s41388-019-0985-1. [Epub ahead of print]

PMID:
31477830
7.

PIDD interaction with KEAP1 as a new mutation-independent mechanism to promote NRF2 stabilization and chemoresistance in NSCLC.

Ji L, Zhang R, Chen J, Xue Q, Moghal N, Tsao MS.

Sci Rep. 2019 Aug 27;9(1):12437. doi: 10.1038/s41598-019-48763-4.

8.

Multiple bone metastases: what the palliative care specialist should know about the potential, limitations and practical aspects of radiation therapy.

Tsao MN, Barnes EA, Chow E.

Ann Palliat Med. 2019 Aug 8. pii: apm.2019.07.09. doi: 10.21037/apm.2019.07.09. [Epub ahead of print]

9.

A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229).

Chia S, Bedard PL, Hilton J, Amir E, Gelmon K, Goodwin R, Villa D, Cabanero M, Tu D, Tsao M, Seymour L.

Oncologist. 2019 Aug 16. pii: theoncologist.2019-0321. doi: 10.1634/theoncologist.2019-0321. [Epub ahead of print]

PMID:
31420468
10.

Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population-based reflex testing.

Fiset PO, Labbé C, Young K, Craddock KJ, Smith AC, Tanguay J, Pintilie M, Wang R, Torlakovic E, Cheung C, da Cunha Santos G, Ko HM, Boerner SL, Hwang DM, Leighl NB, Tsao MS.

Cancer. 2019 Aug 7. doi: 10.1002/cncr.32422. [Epub ahead of print]

PMID:
31390053
11.

"Interchangeability" of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy.

Torlakovic E, Lim HJ, Adam J, Barnes P, Bigras G, Chan AWH, Cheung CC, Chung JH, Couture C, Fiset PO, Fujimoto D, Han G, Hirsch FR, Ilie M, Ionescu D, Li C, Munari E, Okuda K, Ratcliffe MJ, Rimm DL, Ross C, Røge R, Scheel AH, Soo RA, Swanson PE, Tretiakova M, To KF, Vainer GW, Wang H, Xu Z, Zielinski D, Tsao MS.

Mod Pathol. 2019 Aug 5. doi: 10.1038/s41379-019-0327-4. [Epub ahead of print] Review.

PMID:
31383961
12.

CD45+CD326+ Cells are Predictive of Poor Prognosis in Non-Small Cell Lung Cancer Patients.

Ishizawa K, Yamanaka M, Saiki Y, Miyauchi E, Fukushige S, Akaishi T, Asao A, Mimori T, Saito R, Tojo Y, Yamashita R, Abe M, Sakurada A, Pham NA, Li M, Okada Y, Ishii T, Ishii N, Kobayashi S, Nagasaki M, Ichinose M, Tsao MS, Horii A.

Clin Cancer Res. 2019 Aug 5. doi: 10.1158/1078-0432.CCR-19-0545. [Epub ahead of print]

PMID:
31383733
13.

Malignant mesothelioma in situ: morphologic features and clinical outcome.

Churg A, Galateau-Salle F, Roden AC, Attanoos R, von der Thusen JH, Tsao MS, Chang N, De Perrot M, Dacic S.

Mod Pathol. 2019 Aug 2. doi: 10.1038/s41379-019-0347-0. [Epub ahead of print]

PMID:
31375770
14.

Somatic Alteration Burden Involving Non-Cancer Genes Predicts Prognosis in Early-Stage Non-Small Cell Lung Cancer.

Wang D, Pham NA, Freeman TM, Raghavan V, Navab R, Chang J, Zhu CQ, Ly D, Tong J, Wouters BG, Pintilie M, Moran MF, Liu G, Shepherd FA, Tsao MS.

Cancers (Basel). 2019 Jul 19;11(7). pii: E1009. doi: 10.3390/cancers11071009.

15.

Radiation for below the knee skin cancers: a single institution experience.

Barnes EA, Sinclair E, Assaad D, Fialkov J, Antonyshyn O, Tsao MN.

J Dermatolog Treat. 2019 Jul 22:1-4. doi: 10.1080/09546634.2019.1641582. [Epub ahead of print]

PMID:
31294616
16.

Investigation of Leukocyte Telomere Length and Genetic Variants in Chromosome 5p15.33 as Prognostic Markers in Lung Cancer.

Kachuri L, Helby J, Bojesen SE, Christiani DC, Su L, Wu X, Tardón A, Fernández-Tardón G, Field JK, Davies MP, Chen C, Goodman GE, Shepherd FA, Leighl NB, Tsao MS, Brhane Y, Brown MC, Boyd K, Shepshelovich D, Sun L, Amos CI, Liu G, Hung RJ.

Cancer Epidemiol Biomarkers Prev. 2019 Jul;28(7):1228-1237. doi: 10.1158/1055-9965.EPI-18-1215.

PMID:
31263055
17.

Pathologic Considerations and Standardization in Mesothelioma Clinical Trials.

Tsao MS, Carbone M, Galateau-Salle F, Moreira AL, Nicholson AG, Roden AC, Adjei AA, Aubry MC, Fennell DA, Gomez D, Harpole D, Hesdorffer M, Hirsch FR, Liu G, Malik S, Nowak A, Peikert T, Salgia R, Szlosarek P, Taioli E, Yang H, Tsao A, Mansfield AS.

J Thorac Oncol. 2019 Oct;14(10):1704-1717. doi: 10.1016/j.jtho.2019.06.020. Epub 2019 Jun 28.

PMID:
31260832
18.

Computer-assisted image analysis of the tumor microenvironment on an oral tongue squamous cell carcinoma tissue microarray.

Lee SL, Cabanero M, Hyrcza M, Butler M, Liu FF, Hansen A, Huang SH, Tsao MS, Song Y, Lu L, Xu W, Chepeha DB, Goldstein DP, Weinreb I, Bratman SV.

Clin Transl Radiat Oncol. 2019 May 18;17:32-39. doi: 10.1016/j.ctro.2019.05.001. eCollection 2019 Jul.

19.

Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts.

Mer AS, Ba-Alawi W, Smirnov P, Wang YX, Brew B, Ortmann J, Tsao MS, Cescon DW, Goldenberg A, Haibe-Kains B.

Cancer Res. 2019 Sep 1;79(17):4539-4550. doi: 10.1158/0008-5472.CAN-19-0349. Epub 2019 May 29.

PMID:
31142512
20.

Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.

Melosky B, Juergens R, Hirsh V, McLeod D, Leighl N, Tsao MS, Card PB, Chu Q.

Oncologist. 2019 May 28. pii: theoncologist.2019-0027. doi: 10.1634/theoncologist.2019-0027. [Epub ahead of print]

PMID:
31138727
21.

LOXL1 Is Regulated by Integrin α11 and Promotes Non-Small Cell Lung Cancer Tumorigenicity.

Zeltz C, Pasko E, Cox TR, Navab R, Tsao MS.

Cancers (Basel). 2019 May 22;11(5). pii: E705. doi: 10.3390/cancers11050705.

22.

Symptom correlates of dyspnea in advanced cancer patients using the Edmonton Symptom Assessment System.

McKenzie E, Zhang L, Chan S, Zaki P, Razvi Y, Tsao M, Barnes E, Drost L, Yee C, Hwang M, DeAngelis C, Chow E.

Support Care Cancer. 2019 Apr 13. doi: 10.1007/s00520-019-04787-0. [Epub ahead of print]

PMID:
30982093
23.

Characterization of Distinct Populations of Carcinoma-Associated Fibroblasts from Non-Small Cell Lung Carcinoma Reveals a Role for ST8SIA2 in Cancer Cell Invasion.

Hao J, Zeltz C, Pintilie M, Li Q, Sakashita S, Wang T, Cabanero M, Martins-Filho SN, Wang DY, Pasko E, Venkat K, Joseph J, Raghavan V, Zhu CQ, Wang YH, Moghal N, Tsao MS, Navab R.

Neoplasia. 2019 May;21(5):482-493. doi: 10.1016/j.neo.2019.03.009. Epub 2019 Apr 9.

24.

Evosep One Enables Robust Deep Proteome Coverage Using Tandem Mass Tags while Significantly Reducing Instrument Time.

Krieger JR, Wybenga-Groot LE, Tong J, Bache N, Tsao MS, Moran MF.

J Proteome Res. 2019 May 3;18(5):2346-2353. doi: 10.1021/acs.jproteome.9b00082. Epub 2019 Apr 12.

PMID:
30938160
25.

A study of ALK-positive pulmonary squamous-cell carcinoma: From diagnostic methodologies to clinical efficacy.

Wang H, Sun L, Sang Y, Yang X, Tian G, Wang Z, Fang J, Sun W, Zhou L, Jia L, Tsao MS, Shi H, Lin D.

Lung Cancer. 2019 Apr;130:135-142. doi: 10.1016/j.lungcan.2019.02.015. Epub 2019 Feb 18.

PMID:
30885334
26.

Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade.

Fang L, Ly D, Wang SS, Lee JB, Kang H, Xu H, Yao J, Tsao MS, Liu W, Zhang L.

J Exp Clin Cancer Res. 2019 Mar 11;38(1):123. doi: 10.1186/s13046-019-1126-y.

27.

Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer.

Laurie SA, Banerji S, Blais N, Brule S, Cheema PK, Cheung P, Daaboul N, Hao D, Hirsh V, Juergens R, Laskin J, Leighl N, MacRae R, Nicholas G, Roberge D, Rothenstein J, Stewart DJ, Tsao MS.

Curr Oncol. 2019 Feb;26(1):e81-e93. doi: 10.3747/co.26.4116. Epub 2019 Feb 1.

28.

Outcomes of Long-term Interval Rescreening With Low-Dose Computed Tomography for Lung Cancer in Different Risk Cohorts.

Aggarwal R, Lam ACL, McGregor M, Menezes R, Hueniken K, Tateishi H, O'Kane GM, Tsao MS, Shepherd FA, Xu W, McInnis M, Schmidt H, Liu G, Kavanagh J.

J Thorac Oncol. 2019 Jun;14(6):1003-1011. doi: 10.1016/j.jtho.2019.01.031. Epub 2019 Feb 13.

PMID:
30771523
29.

Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer.

Tomasini P, Mascaux C, Jao K, Labbe C, Kamel-Reid S, Stockley T, Hwang DM, Leighl NB, Liu G, Bradbury PA, Pintilie M, Tsao MS, Shepherd FA.

Clin Lung Cancer. 2019 May;20(3):e338-e345. doi: 10.1016/j.cllc.2018.12.009. Epub 2018 Dec 19.

PMID:
30770327
30.

Elevated Platelet Count Appears to Be Causally Associated with Increased Risk of Lung Cancer: A Mendelian Randomization Analysis.

Zhu Y, Wei Y, Zhang R, Dong X, Shen S, Zhao Y, Bai J, Albanes D, Caporaso NE, Landi MT, Zhu B, Chanock SJ, Gu F, Lam S, Tsao MS, Shepherd FA, Tardon A, Fernández-Somoano A, Fernandez-Tardon G, Chen C, Barnett MJ, Doherty J, Bojesen SE, Johansson M, Brennan P, McKay JD, Carreras-Torres R, Muley T, Risch A, Wichmann HE, Bickeboeller H, Rosenberger A, Rennert G, Saliba W, Arnold SM, Field JK, Davies MPA, Marcus MW, Wu X, Ye Y, Le Marchand L, Wilkens LR, Melander O, Manjer J, Brunnström H, Hung RJ, Liu G, Brhane Y, Kachuri L, Andrew AS, Duell EJ, Kiemeney LA, van der Heijden EH, Haugen A, Zienolddiny S, Skaug V, Grankvist K, Johansson M, Woll PJ, Cox A, Taylor F, Teare DM, Lazarus P, Schabath MB, Aldrich MC, Houlston RS, McLaughlin J, Stevens VL, Shen H, Hu Z, Dai J, Amos CI, Han Y, Zhu D, Goodman GE, Chen F, Christiani DC.

Cancer Epidemiol Biomarkers Prev. 2019 May;28(5):935-942. doi: 10.1158/1055-9965.EPI-18-0356. Epub 2019 Jan 30.

PMID:
30700444
31.

Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15.

Yao J, Ly D, Dervovic D, Fang L, Lee JB, Kang H, Wang YH, Pham NA, Pan H, Tsao MS, Zhang L.

J Immunother Cancer. 2019 Jan 22;7(1):17. doi: 10.1186/s40425-019-0507-2.

32.

Health-related quality of life and anxiety in the PAN-CAN lung cancer screening cohort.

Taghizadeh N, Tremblay A, Cressman S, Peacock S, McWilliams AM, MacEachern P, Johnston MR, Goffin J, Goss G, Nicholas G, Martel S, Laberge F, Bhatia R, Liu G, Schmidt H, Atkar-Khattra S, Tsao MS, Tammemagi MC, Lam SC; Pan-Canadian Early Lung Cancer Study Group.

BMJ Open. 2019 Jan 17;9(1):e024719. doi: 10.1136/bmjopen-2018-024719.

33.

ONECUT2 is a driver of neuroendocrine prostate cancer.

Guo H, Ci X, Ahmed M, Hua JT, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E, Su P, Chen S, Nguyen T, Liang Y, Zhang Y, Xu X, Xu J, Sheahan AV, Ba-Alawi W, Zhang S, Mahamud O, Vellanki RN, Gleave M, Bristow RG, Haibe-Kains B, Poirier JT, Rudin CM, Tsao MS, Wouters BG, Fazli L, Feng FY, Ellis L, van der Kwast T, Berlin A, Koritzinsky M, Boutros PC, Zoubeidi A, Beltran H, Wang Y, He HH.

Nat Commun. 2019 Jan 17;10(1):278. doi: 10.1038/s41467-018-08133-6.

34.

Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation.

Kano Y, Gebregiworgis T, Marshall CB, Radulovich N, Poon BPK, St-Germain J, Cook JD, Valencia-Sama I, Grant BMM, Herrera SG, Miao J, Raught B, Irwin MS, Lee JE, Yeh JJ, Zhang ZY, Tsao MS, Ikura M, Ohh M.

Nat Commun. 2019 Jan 15;10(1):224. doi: 10.1038/s41467-018-08115-8.

35.

Whole genomes define concordance of matched primary, xenograft, and organoid models of pancreas cancer.

Gendoo DMA, Denroche RE, Zhang A, Radulovich N, Jang GH, Lemire M, Fischer S, Chadwick D, Lungu IM, Ibrahimov E, Cao PJ, Stein LD, Wilson JM, Bartlett JMS, Tsao MS, Dhani N, Hedley D, Gallinger S, Haibe-Kains B.

PLoS Comput Biol. 2019 Jan 10;15(1):e1006596. doi: 10.1371/journal.pcbi.1006596. eCollection 2019 Jan.

36.

Systematic analyses of regulatory variants in DNase I hypersensitive sites identified two novel lung cancer susceptibility loci.

Dai J, Li Z, Amos CI, Hung RJ, Tardon A, Andrew AS, Chen C, Christiani DC, Albanes D, van der Heijden EHFM, Duell EJ, Rennert G, Mckay JD, Yuan JM, Field JK, Manjer J, Grankvist K, Le Marchand L, Teare MD, Schabath MB, Aldrich MC, Tsao MS, Lazarus P, Lam S, Bojesen SE, Arnold S, Wu X, Haugen A, Janout V, Johansson M, Brhane Y, Fernandez-Somoano A, Kiemeney LA, Davies MPA, Zienolddiny S, Hu Z, Shen H.

Carcinogenesis. 2019 May 14;40(3):432-440. doi: 10.1093/carcin/bgy187.

PMID:
30590402
37.

Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer.

Yatabe Y, Dacic S, Borczuk AC, Warth A, Russell PA, Lantuejoul S, Beasley MB, Thunnissen E, Pelosi G, Rekhtman N, Bubendorf L, Mino-Kenudson M, Yoshida A, Geisinger KR, Noguchi M, Chirieac LR, Bolting J, Chung JH, Chou TY, Chen G, Poleri C, Lopez-Rios F, Papotti M, Sholl LM, Roden AC, Travis WD, Hirsch FR, Kerr KM, Tsao MS, Nicholson AG, Wistuba I, Moreira AL.

J Thorac Oncol. 2019 Mar;14(3):377-407. doi: 10.1016/j.jtho.2018.12.005. Epub 2018 Dec 18.

PMID:
30572031
38.

Stability and degradation products of imipenem applying high-resolution mass spectrometry: An analytical study focused on solutions for infusion.

de Souza Barbosa F, Capra Pezzi L, Tsao M, Franco de Oliveira T, Manoela Dias Macedo S, E S Schapoval E, S L Mendez A.

Biomed Chromatogr. 2019 Apr;33(4):e4471. doi: 10.1002/bmc.4471. Epub 2019 Jan 7.

PMID:
30549056
39.

Are we better a decade later in the accuracy of survival prediction by palliative radiation oncologists?

Razvi Y, Chan S, Zhang L, Tsao M, Barnes E, Danjoux C, Sousa P, Zaki P, McKenzie E, Lam H, DeAngelis C, Chow E.

Ann Palliat Med. 2019 Apr;8(2):150-158. doi: 10.21037/apm.2018.11.02. Epub 2018 Nov 21.

40.

Re-analysis of symptom clusters in advanced cancer patients attending a palliative outpatient radiotherapy clinic.

McKenzie E, Zhang L, Zaki P, Chan S, Ganesh V, Razvi Y, Tsao M, Barnes E, Hwang MK, DeAngelis C, Chow E.

Ann Palliat Med. 2019 Apr;8(2):140-149. doi: 10.21037/apm.2018.08.06. Epub 2018 Sep 5.

41.

Canadian perspectives: update on inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.

Melosky B, Cheema P, Agulnik J, Albadine R, Bebb DG, Blais N, Burkes R, Butts C, Card PB, Chan AMY, Hirsh V, Ionescu DN, Juergens R, Morzycki W, Poonja Z, Sangha R, Tehfe M, Tsao MS, Vincent M, Xu Z, Liu G.

Curr Oncol. 2018 Oct;25(5):317-328. doi: 10.3747/co.25.4379. Epub 2018 Oct 31. Review.

42.

Pediatric airway management devices: an update on recent advances and future directions.

Tsao M, Vargas AA, Hajduk J, Singh R, Jagannathan N.

Expert Rev Med Devices. 2018 Dec;15(12):911-927. doi: 10.1080/17434440.2018.1549483. Epub 2018 Nov 29. Review.

PMID:
30451031
43.

LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non-small-cell Lung Cancer.

Seymour L, Le Teuff G, Brambilla E, Shepherd FA, Soria JC, Kratzke R, Graziano S, Douillard JY, Rosell R, Reiman A, Lacas B, Lueza B, Aviel-Ronen S, McLeer A, Le Chevalier T, Pirker R, Filipits M, Dunant A, Pignon JP, Tsao MS; LACE-Bio Steering Committee.

Clin Lung Cancer. 2019 Mar;20(2):66-73.e6. doi: 10.1016/j.cllc.2018.10.001. Epub 2018 Oct 11.

PMID:
30414783
44.

Predicting Malignancy Risk of Screen-Detected Lung Nodules-Mean Diameter or Volume.

Tammemagi M, Ritchie AJ, Atkar-Khattra S, Dougherty B, Sanghera C, Mayo JR, Yuan R, Manos D, McWilliams AM, Schmidt H, Gingras M, Pasian S, Stewart L, Tsai S, Seely JM, Burrowes P, Bhatia R, Haider EA, Boylan C, Jacobs C, van Ginneken B, Tsao MS, Lam S; Pan-Canadian Early Detection of Lung Cancer Study Group.

J Thorac Oncol. 2019 Feb;14(2):203-211. doi: 10.1016/j.jtho.2018.10.006. Epub 2018 Oct 25.

PMID:
30368011
45.

Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.

Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE, de Perrot M, Fennell DA, Friedberg J, Gill RR, Gomez DR, Harpole DH Jr, Hassan R, Hesdorffer M, Hirsch FR, Hmeljak J, Kindler HL, Korn EL, Liu G, Mansfield AS, Nowak AK, Pass HI, Peikert T, Rimner A, Robinson BWS, Rosenzweig KE, Rusch VW, Salgia R, Sepesi B, Simone CB 2nd, Sridhara R, Szlosarek P, Taioli E, Tsao MS, Yang H, Zauderer MG, Malik SM.

J Thorac Oncol. 2018 Nov;13(11):1655-1667. doi: 10.1016/j.jtho.2018.08.2036. Epub 2018 Sep 25.

PMID:
30266660
46.

Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity.

Ferreiro-Iglesias A, Lesseur C, McKay J, Hung RJ, Han Y, Zong X, Christiani D, Johansson M, Xiao X, Li Y, Qian DC, Ji X, Liu G, Caporaso N, Scelo G, Zaridze D, Mukeriya A, Kontic M, Ognjanovic S, Lissowska J, Szołkowska M, Swiatkowska B, Janout V, Holcatova I, Bolca C, Savic M, Ognjanovic M, Bojesen SE, Wu X, Albanes D, Aldrich MC, Tardon A, Fernandez-Somoano A, Fernandez-Tardon G, Le Marchand L, Rennert G, Chen C, Doherty J, Goodman G, Bickeböller H, Wichmann HE, Risch A, Rosenberger A, Shen H, Dai J, Field JK, Davies M, Woll P, Teare MD, Kiemeney LA, van der Heijden EHFM, Yuan JM, Hong YC, Haugen A, Zienolddiny S, Lam S, Tsao MS, Johansson M, Grankvist K, Schabath MB, Andrew A, Duell E, Melander O, Brunnström H, Lazarus P, Arnold S, Slone S, Byun J, Kamal A, Zhu D, Landi MT, Amos CI, Brennan P.

Nat Commun. 2018 Sep 25;9(1):3927. doi: 10.1038/s41467-018-05890-2.

47.

Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma.

Yu H, Chen Z, Ballman KV, Watson MA, Govindan R, Lanc I, Beer DG, Bueno R, Chirieac LR, Chui MH, Chen G, Franklin WA, Gandara DR, Genova C, Brovsky KA, Joshi MM, Merrick DT, Richards WG, Rivard CJ, Harpole DH, Tsao MS, van Bokhoven A, Shepherd FA, Hirsch FR.

J Thorac Oncol. 2019 Jan;14(1):25-36. doi: 10.1016/j.jtho.2018.09.006. Epub 2018 Sep 22.

PMID:
30253973
48.

A review of the Rapid Response Radiotherapy Program in patients with advanced cancer referred for palliative radiotherapy over two decades.

Razvi Y, Chan S, Zhang L, Tsao M, Barnes E, Danjoux C, Sousa P, Zaki P, McKenzie E, DeAngelis C, Chow E.

Support Care Cancer. 2019 Jun;27(6):2131-2134. doi: 10.1007/s00520-018-4474-9. Epub 2018 Sep 24. Review.

PMID:
30246224
49.

Omega-3 Fatty Acids Prevent Early Pancreatic Carcinogenesis via Repression of the AKT Pathway.

Ding Y, Mullapudi B, Torres C, Mascariñas E, Mancinelli G, Diaz AM, McKinney R, Barron M, Schultz M, Heiferman M, Wojtanek M, Adrian K, DeCant B, Rao S, Ouellette M, Tsao MS, Bentrem DJ, Grippo PJ.

Nutrients. 2018 Sep 12;10(9). pii: E1289. doi: 10.3390/nu10091289.

50.

Refined RIP-seq protocol for epitranscriptome analysis with low input materials.

Zeng Y, Wang S, Gao S, Soares F, Ahmed M, Guo H, Wang M, Hua JT, Guan J, Moran MF, Tsao MS, He HH.

PLoS Biol. 2018 Sep 13;16(9):e2006092. doi: 10.1371/journal.pbio.2006092. eCollection 2018 Sep.

Supplemental Content

Support Center